Have a personal or library account? Click to login
Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperfused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country Cover

Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperfused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country

Global Heart
Volume 15 (2020): Issue 1
By: Sylvi Irawati,  Surya Dharma,  Katja Taxis,  Thang Nguyen,  Nunung Nursyarofah,  Bob Wilffert and  Eelko Hak  
Open Access
|Feb 2020

References

  1. 1GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–71. DOI: 10.1016/S0140-6736(14)61682-2
    Back to article
  2. 2The World Bank Group. World Bank analytical classifications (presented in World Development Indicators). 2015. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed 20 June 2018).
    Back to article
  3. 3Richmond Vale Academy. List of developing countries in 2016. 2018 http://richmondvale.org/developing-countries-list/ (accessed 19 June 2018).
    Back to article
  4. 4GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053): 1459–544. DOI: 10.1016/S0140-6736(16)31012-1
    Back to article
  5. 5World Health Organization. Global health estimates 2015: deaths by cause, age, sex, by country and by region, 2000–2015. 2016 http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html (accessed 20 June 2018).
    Back to article
  6. 6Martinez R, Soliz P, Caixeta R, et al. Reflection on modern methods: years of life lost due to premature mortality: a versatile and comprehensive measure for monitoring non-communicable disease mortality. Int J Epidemiol. 2019; 48(4): 1367–76. DOI: 10.1093/ije/dyy254
    Back to article
  7. 7Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256. DOI: 10.21037/atm.2016.06.33
    Back to article
  8. 8Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64(24): e139–228.
    Back to article
  9. 9O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61(4): 78–140. DOI: 10.1016/j.jacc.2012.11.019
    Back to article
  10. 10Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016; 37(3): 267–315. DOI: 10.1093/eurheartj/ehv320
    Back to article
  11. 11Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017; 00: 1–66. DOI: 10.1016/j.rec.2017.11.010
    Back to article
  12. 12Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation. 2014; 129(14): 1493–501. DOI: 10.1161/CIRCULATIONAHA.113.004046
    Back to article
  13. 13Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006; 333(7578): 1091. DOI: 10.1136/bmj.38985.646481.55
    Back to article
  14. 14Dasari TW, Hamilton S, Chen AY, et al. Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: contemporary insights from the National Cardiovascular Data Registry (NCDR). Am Heart J. 2016; 172: 1–8. DOI: 10.1016/j.ahj.2015.10.014
    Back to article
  15. 15Huo Y, Thompson P, Buddhari W, et al. Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. Int J Cardiol. 2015; 183(2015): 63–75. DOI: 10.1016/j.ijcard.2014.11.195
    Back to article
  16. 16Dharma S, Juzar DA, Firdaus I, et al. Acute myocardial infarction system of care in the third world. Neth Heart J. 2012; 20(6): 254–9. DOI: 10.1007/s12471-012-0259-9
    Back to article
  17. 17Dharma S, Andriantoro H, Dakota I, et al. Organisation of reperfusion therapy for STEMI in a developing country. Open Heart. 2015; 2(1): e000240. DOI: 10.1136/openhrt-2015-000240
    Back to article
  18. 18Dharma S, Andriantoro H, Purnawan I, et al. Characteristics, treatment and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. BMJ Open. 2016; 6(8): e012193. DOI: 10.1136/bmjopen-2016-012193corr1
    Back to article
  19. 19Dharma S, Siswanto BB, Firdaus I, et al. Temporal trends of system of care for STEMI: Insights from the Jakarta Cardiovascular Care Unit Network system. PLoS One. 2014; 9(2): 1–5. DOI: 10.1371/journal.pone.0086665
    Back to article
  20. 20Nguyen T, Le KK, Cao HTK, et al. Association between in-hospital guideline adherence and postdischarge major adverse outcomes of patients with acute coronary syndrome in Vietnam: a prospective cohort study. BMJ Open. 2017; 7(10): e017008. DOI: 10.1136/bmjopen-2017-017008
    Back to article
  21. 21Alter DA, Ko DT, Newman A, et al. Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction. Eur Hear J. 2006; 27(13): 1539–49. DOI: 10.1093/eurheartj/ehl066
    Back to article
  22. 22Fox KAA, Eagle KA, Gore JM, et al. The global registry of acute coronary events, 1999 to 2009-GRACE. Heart. 2010; 96(14): 1095–101. DOI: 10.1136/hrt.2009.190827
    Back to article
  23. 23Kristensen SD, Laut KG, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. Eur Heart J. 2014; 35(29): 1957–70. DOI: 10.1093/eurheartj/eht529
    Back to article
  24. 24Schömig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005; 293(23): 2865–72. DOI: 10.1001/jama.293.23.2865
    Back to article
  25. 25Cohen M, Boiangiu C, Abidi M. Therapy for ST-segment elevation myocardial infarction patients who present late or are ineligible for reperfusion therapy. J Am Coll Cardiol. 2010; 55(18): 1895–906. DOI: 10.1016/j.jacc.2009.11.087
    Back to article
  26. 26Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a Prospective National Observational Study [PL-ACS]). Am J Cardiol. 2011; 107(4): 501–8. DOI: 10.1016/j.amjcard.2010.10.008
    Back to article
  27. 27Bugiardini R, Dorobantu M, Vasiljevic Z, et al. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy. Atherosclerosis. 2015; 241: 151–6. DOI: 10.1016/j.atherosclerosis.2015.04.794
    Back to article
  28. 28COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1607–21. DOI: 10.1016/S0140-6736(05)67660-X
    Back to article
  29. 29Oldgren J, Wallentin L, Afzal R, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J. 2008; 29(3): 315–23. DOI: 10.1093/eurheartj/ehm578
    Back to article
  30. 30Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol. 2003; 42(8): 1348–56. DOI: 10.1016/S0735-1097(03)01040-4
    Back to article
  31. 31Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4(10): 1628–54. DOI: 10.1371/journal.pmed.0040297
    Back to article
  32. 32Indonesian Heart Association. Pedoman tatalaksana sindrom koroner akut. 2015. http://www.inaheart.org/upload/file/Pedoman_tatalaksana_Sindrom_Koroner_Akut_2015.pdf (accessed 13 Nov 2017).
    Back to article
  33. 33Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–619. DOI: 10.1093/eurheartj/ehs215
    Back to article
  34. 34Li M, Li S, Du X, et al. Factors attributed to the higher in-hospital mortality of ST elevation myocardial infarction patients admitted during off-hour in comparison with those during regular hour. PLoS One [Internet]. 2017; 12(4): e0175485. DOI: 10.1371/journal.pone.0175485
    Back to article
  35. 35Huffman MD, Prabhakaran D, Abraham A, et al. Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: Results from the Kerala ACS Registry. Circ Cardiovasc Qual Outcomes. 2013; 6(4): 436–43. DOI: 10.1161/CIRCOUTCOMES.113.000189
    Back to article
  36. 36Hall M, Bebb OJ, Dondo TB, et al. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. Eur Heart J. 2018; 39(42): 3798–806. DOI: 10.1093/eurheartj/ehy517
    Back to article
  37. 37Tomasevic D, El Khoury C, Subtil F, et al. Effect of optimal medical therapy at discharge in patients with reperfused ST-segment elevation myocardial infarction on 1-year mortality (from the Regional RESCUe Registry). Am J Cardiol. 2018; 121(4): 403–9. DOI: 10.1016/j.amjcard.2017.11.002
    Back to article
  38. 38Saar A, Marandi T, Ainla T, et al. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. Int J Cardiol. 2018; 272: 26–32. DOI: 10.1016/j.ijcard.2018.08.015
    Back to article
  39. 39Roffi M, Mukherjee D. Treatment-risk paradox in acute coronary syndromes. Eur Heart J. 2018; 39(42): 3807–9. DOI: 10.1093/eurheartj/ehy577
    Back to article
  40. 40Bauer T, Gitt AK, Jünger C, et al. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil. 2010; 17(5): 576–81. DOI: 10.1097/HJR.0b013e328338e5da
    Back to article
  41. 41Sainani KL. Understanding odds ratios. PM&R. 2011; 3(3): 263–7. DOI: 10.1016/j.pmrj.2011.01.009
    Back to article
  42. 42Zhang J, Yun KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998; 280(19): 1690–1. DOI: 10.1001/jama.280.19.1690
    Back to article
  43. 43Schiele F, Meneveau N, Seronde MF, et al. Compliance with guidelines and 1-year mortality in patients with acute myocardial infarction: A prospective study. Eur Heart J. 2005; 26(9): 873–80. DOI: 10.1093/eurheartj/ehi107
    Back to article
  44. 44Nguyen T, Nguyen TH, Pham HTK, et al. Physicians’ adherence to acute coronary syndrome prescribing guidelines in Vietnamese hospital practice: a cross-sectional study. Trop Med Int Health. 2015; 20(5): 627–37. DOI: 10.1111/tmi.12467
    Back to article
  45. 45Mehta SR, Bassand J, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2018; 156(6): 1080–88.e1. DOI: 10.1016/j.ahj.2008.07.026
    Back to article
  46. 46Wang Y, Fu R, Wang Z, et al. Assessing the quality of care for patients with acute myocardial infarction in China. Clin Cardiol. 2015; 38(6): 327–32. DOI: 10.1002/clc.22405
    Back to article
DOI: https://doi.org/10.5334/gh.394 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Jun 27, 2019
Accepted on: Oct 23, 2019
Published on: Feb 6, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
ST-elevation myocardial infarction,
STEMI,
no reperfusion therapy,
guideline adherence,
hospital mortality,
Indonesia,
developing countries

© 2020 Sylvi Irawati, Surya Dharma, Katja Taxis, Thang Nguyen, Nunung Nursyarofah, Bob Wilffert, Eelko Hak, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 15 (2020): Issue 1Next article